A citation-based method for searching scientific literature

Michael Choi, Thomas Kipps, Razelle Kurzrock. Mol Cancer Ther 2016
Times Cited: 217







List of co-cited articles
800 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
Shuhei Matsuoka, Bryan A Ballif, Agata Smogorzewska, E Robert McDonald, Kristen E Hurov, Ji Luo, Corey E Bakalarski, Zhenming Zhao, Nicole Solimini, Yaniv Lerenthal,[...]. Science 2007
13

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
12

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
11

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
10

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
10



ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Nicholas R Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Kolinsky, Gareth J Williams, Pinaki Bose, Susan P Lees-Miller. Cancers (Basel) 2020
44
22

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
10

COSMIC: the Catalogue Of Somatic Mutations In Cancer.
John G Tate, Sally Bamford, Harry C Jubb, Zbyslaw Sondka, David M Beare, Nidhi Bindal, Harry Boutselakis, Charlotte G Cole, Celestino Creatore, Elisabeth Dawson,[...]. Nucleic Acids Res 2019
9

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
9

The DNA damage response: making it safe to play with knives.
Alberto Ciccia, Stephen J Elledge. Mol Cell 2010
8

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A Yazinski, Valentine Comaills, Rémi Buisson, Marie-Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig,[...]. Genes Dev 2017
191
8

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Frank P Vendetti, Alan Lau, Sandra Schamus, Thomas P Conrads, Mark J O'Connor, Christopher J Bakkenist. Oncotarget 2015
134
8

State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap. Nat Rev Clin Oncol 2019
366
8

Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage.
Jacob Falck, Julia Coates, Stephen P Jackson. Nature 2005
917
8

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
756
8

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Timothy A Yap, Brent O'Carrigan, Marina S Penney, Joline S Lim, Jessica S Brown, Maria J de Miguel Luken, Nina Tunariu, Raquel Perez-Lopez, Daniel Nava Rodrigues, Ruth Riisnaes,[...]. J Clin Oncol 2020
59
13


Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Philip M Reaper, Matthew R Griffiths, Joanna M Long, Jean-Damien Charrier, Somhairle Maccormick, Peter A Charlton, Julian M C Golec, John R Pollard. Nat Chem Biol 2011
402
7


PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
7

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
7

ATM mutations in patients with hereditary pancreatic cancer.
Nicholas J Roberts, Yuchen Jiao, Jun Yu, Levy Kopelovich, Gloria M Petersen, Melissa L Bondy, Steven Gallinger, Ann G Schwartz, Sapna Syngal, Michele L Cote,[...]. Cancer Discov 2012
309
7

A single ataxia telangiectasia gene with a product similar to PI-3 kinase.
K Savitsky, A Bar-Shira, S Gilad, G Rotman, Y Ziv, L Vanagaite, D A Tagle, S Smith, T Uziel, S Sfez,[...]. Science 1995
7


Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
7

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
7

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Andrew N Blackford, Stephen P Jackson. Mol Cell 2017
730
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
7

ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1.
Zhongsheng You, Charly Chahwan, Julie Bailis, Tony Hunter, Paul Russell. Mol Cell Biol 2005
318
6

A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Daniel L Menezes, Jenny Holt, Yan Tang, Jiajia Feng, Paul Barsanti, Yue Pan, Majid Ghoddusi, Wei Zhang, George Thomas, Jocelyn Holash,[...]. Mol Cancer Res 2015
54
11

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
E Fokas, R Prevo, J R Pollard, P M Reaper, P A Charlton, B Cornelissen, K A Vallis, E M Hammond, M M Olcina, W Gillies McKenna,[...]. Cell Death Dis 2012
221
6

An oncogene-induced DNA damage model for cancer development.
Thanos D Halazonetis, Vassilis G Gorgoulis, Jiri Bartek. Science 2008
6

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Chris T Williamson, Eiji Kubota, Jeffrey D Hamill, Alexander Klimowicz, Ruiqiong Ye, Huong Muzik, Michelle Dean, LiRen Tu, David Gilley, Anthony M Magliocco,[...]. EMBO Mol Med 2012
98
6

ATM and ATR as therapeutic targets in cancer.
Anika Maria Weber, Anderson Joseph Ryan. Pharmacol Ther 2015
329
6

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
6

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Victoria J Weston, Ceri E Oldreive, Anna Skowronska, David G Oscier, Guy Pratt, Martin J S Dyer, Graeme Smith, Judy E Powell, Zbigniew Rudzki, Pamela Kearns,[...]. Blood 2010
220
6

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.
Patrick G Pilié, Carl M Gay, Lauren A Byers, Mark J O'Connor, Timothy A Yap. Clin Cancer Res 2019
133
6

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
201
6

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Mayu Isono, Endang Nuryadi, Ryota Sekine, Takahiro Oike, Sangeeta Kakoti,[...]. Nat Commun 2017
272
6

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Lukas Perkhofer, Anna Schmitt, Maria Carolina Romero Carrasco, Michaela Ihle, Stephanie Hampp, Dietrich Alexander Ruess, Elisabeth Hessmann, Ronan Russell, André Lechel, Ninel Azoitei,[...]. Cancer Res 2017
61
9

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
Samantha A Armstrong, Christopher W Schultz, Ariana Azimi-Sadjadi, Jonathan R Brody, Michael J Pishvaian. Mol Cancer Ther 2019
31
19

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
865
6


Genomic instability--an evolving hallmark of cancer.
Simona Negrini, Vassilis G Gorgoulis, Thanos D Halazonetis. Nat Rev Mol Cell Biol 2010
6

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
Veronika Navrkalova, Ludmila Sebejova, Jana Zemanova, Jana Kminkova, Blanka Kubesova, Jitka Malcikova, Marek Mraz, Jana Smardova, Sarka Pavlova, Michael Doubek,[...]. Haematologica 2013
31
16

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Frank P Vendetti, Pooja Karukonda, David A Clump, Troy Teo, Ronald Lalonde, Katriana Nugent, Matthew Ballew, Brian F Kiesel, Jan H Beumer, Saumendra N Sarkar,[...]. J Clin Invest 2018
81
6

Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.
Oren Gilad, Barzin Y Nabet, Ryan L Ragland, David W Schoppy, Kevin D Smith, Amy C Durham, Eric J Brown. Cancer Res 2010
156
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.